Supernus, Inc. SUPN
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. 10-K, Item 1
- Headquarters
- Rockville, MD
- CEO
- Jack A. Khattar
- Next results
- around Feb 11, 2027
Where each dollar of revenue went, FY2024
Revenue of $661.8M through the costs to a net profit of $73.9M · income statement of the 10-K
SUPN among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
34 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Mar 2, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +32.2% ($142.1M to $187.8M) vs revenue +8.6% ($661.8M to $719.0M), +23.6 pts apart
-
Inventory growing faster than revenueInventory +107.2% ($54.3M to $112.5M) vs revenue +8.6% ($661.8M to $719.0M), +98.5 pts apart
-
Cash from operations $47.3M vs net income −$38.5M (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Accrued sales deductions related to product returns
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
34 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Third parties have developed, received FDA approval and successfully commercialized longer-lasting extended relief levodopa/carbidopa products, which are impacting sales of APOKYN because they reduce the number of times per day a given patient may need to use an off-episode product like APOKYN. Third parties have also developed,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The commercial results of ZURZUVAE® (zuranolone) depend, in part, on our ability, with our collaboration partner, Biogen MA Inc., and Biogen International GmbH, or together, Biogen, to successfully continue the commercialization of the product for the treatment of women with postpartum depression, or PPD, in the U.S. There is no…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
During 2025 several Executive Orders were issued by the President of the United States, which generally aim to lower the price paid for certain pharmaceutical products in the United States. Aspects of these orders direct the Secretary of Health and Human Services to develop implementation plans and to issue related regulations. We are…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The U.S. and certain states have shown significant, increased interest in pursuing healthcare reform and changes to the healthcare delivery system. Numerous major markets outside the U.S., including the EU, Japan, and China, have widespread governmental involvement in healthcare funding, including with regard to pricing and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $667.2M | $607.5M | $661.8M | $719.0M |
| Net income | $60.7M | $1.3M | $73.9M | −$38.5M |
| Operating cash flow | $116.8M | $111.1M | $172.0M | $47.3M |
| Free cash flow | $116.4M | $110.5M | $171.2M | $46.0M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$719.0M ▲ 8.6% in FY2025−$38.5M in FY2025$46.0M ▼ 73.1% in FY2025
Recent filings
10 filings in the last 30 days · SEC EDGAR
-
8-KNov 2, 2026Material agreement signed, Acquisition or sale of assets completed, New debt or obligation, Shareholder rights changed, Change in control, Bylaws or fiscal year changed, Regulation FD disclosure 8-K items 1.01, 2.01, 2.03, 3.03, 5.01, 5.03, 7.01
-
8-KNov 2, 2026Listing notice 8-K item 3.01
-
Planned saleOct 29, 2026Charles Newhall (Director) ended a 10b5-1 trading plan reported in the 10-Q, up to 5,000 shares
-
Planned saleOct 29, 2026Jack Khattar (President, Chief Executive Officer and Director) ended a 10b5-1 trading plan reported in the 10-Q, up to 297,500 shares
-
Planned saleOct 29, 2026William Todd Horich (Senior Vice President, Chief Commercial Officer) ended a 10b5-1 trading plan reported in the 10-Q, up to 44,000 shares
About the company
Supernus, Inc., Rockville, MD · from the 10-K filed Mar 2, 2026
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.
- Headquarters
- Rockville, MD
- Country
- United States
- Reports in
- USD
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Mar 2, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.